A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

A new study has identified polyphosphate as a likely "mystery density" within fibrils associated with Alzheimer's and other ...

Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

(“Alpha”) of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets ) (“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is ...

Firms developing Alzheimer’s drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be ...

Alpha Cognition Inc. (NASDAQ:ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for ...

The study also integrates drug databases ... Women With Ovarian Removal Have Unique Risk and Resilience Factors for Alzheimer Disease Dec. 5, 2024 — New research has found that women who have ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

A groundbreaking study reveals that concussions and repetitive head injuries in sports could trigger latent viruses in the ...